Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel.
暂无分享,去创建一个
V. Soriano | A. Hatzakis | S. Pol | S. Mauss | M. Peters | M. Sulkowski | M. Puoti | Y. Benhamou | N. Bräu | J. Rockstroh | A. Cargnel
[1] V. Soriano,et al. Liver fibrosis stage and HCV genotype distribution in HIV-HCV coinfected patients with persistently normal transaminases. , 2007, AIDS research and human retroviruses.
[2] V. Soriano,et al. Clearance of hepatitis C virus in HIV‐infected patients with multiple chronic viral hepatitis , 2007, Journal of viral hepatitis.
[3] V. Soriano,et al. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis. , 2007, The Journal of infectious diseases.
[4] L. Waters,et al. 8th International Congress on Drug Therapy in HIV Infection , 2007 .
[5] R. Bonomo,et al. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. , 2007, Future microbiology.
[6] G. Pialoux,et al. Reactivation of hepatitis B virus replication during peginterferon-ribavirin therapy in an HIV/hepatitis C virus-co-infected patient with isolated anti-hepatitis B core antibodies. , 2007, AIDS.
[7] J. Montaner,et al. Histological response to pegIFNα-2a (40KD) plus ribavirin in HIV–hepatitis C virus co-infection , 2006, AIDS.
[8] E. Rosenberg,et al. Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity , 2006, AIDS.
[9] C. Katlama,et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial , 2006, The Lancet.
[10] B. Ledergerber,et al. Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from an Inter-Cohort Analysis , 2006, Antiviral therapy.
[11] R. Andrade,et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. , 2006, Gastroenterology.
[12] H. Jessen,et al. Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients. , 2006, The Journal of infection.
[13] C. Toro,et al. Severe Liver Disease Associated With Prolonged Exposure to Antiretroviral Drugs , 2006, Journal of acquired immune deficiency syndromes.
[14] J. Montaner,et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.
[15] C. Katlama,et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients , 2006, AIDS.
[16] S. Roberts,et al. Sustained virological response rates and durability of the response to interferon‐based therapies in hepatitis C patients treated in the clinical setting , 2006, Journal of viral hepatitis.
[17] A. Folgori,et al. Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years , 2006, Journal of viral hepatitis.
[18] J. Torre-Cisneros,et al. Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir. , 2006, The Journal of antimicrobial chemotherapy.
[19] A. Alberti,et al. Fibrosis progression in initially mild chronic hepatitis C , 2006, Journal of viral hepatitis.
[20] L. McCullagh,et al. Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV‐coinfected individuals * , 2006, HIV medicine.
[21] V. Soriano,et al. Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir. , 2006, AIDS research and human retroviruses.
[22] J. Altés,et al. Efficacy and Safety of Pegylated Interferon-α2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Patients , 2006 .
[23] V. Soriano,et al. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. , 2006, Journal of viral hepatitis.
[24] B. Hunyady,et al. 599 Peg-IFN plus ribavirin therapy suppresses plasma TGF-β1, hyaluronic acid and procollagen-III-peptide levels in patients with chronic hepatitis C independently of virological response , 2006 .
[25] F. Carrat,et al. 558 Risk factors for bacterial infections in HIV/HCV-coinfected patients during interferon plus ribavirin-based therapy , 2006 .
[26] T. Berg,et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. , 2006, Gastroenterology.
[27] R. Fontana. Optimizing outcomes in hepatitis C: is treatment beyond 48 weeks ever justified? , 2006, Gastroenterology.
[28] V. Soriano,et al. Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] S. Zeuzem,et al. 734 Peginterferon alpha-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 OR 3. Final results of the accelerate trial , 2006 .
[30] C. Datz,et al. 8 24 Week treatment regimen with peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in HCV genotype 1 or 4 ‘super-responders’ , 2006 .
[31] J. Albrecht,et al. 744 Sustained virologic response (SVR) to interferon-alpha-2b +/- ribavirin therapy at 6 months reliably predicts long-term clearance of HCV at 5-year follow-up , 2006 .
[32] V. Bourcier,et al. 577 Liver stiffness measurement (LSM) as a tool to measure liver fibrosis in treated patients with chronic hepatitis C (CHC) , 2006 .
[33] P. Marcellin,et al. 11 Efficacy of standard-dose and fixed-dose induction peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) among pegylated interferon alpha-2b (12kd)/ribavirin non-responders: Interim analysis of the repeat study , 2006 .
[34] P. Couzigou,et al. 564 Evaluation of fibrosis regression using fibroscan in HCV responder patients. A prospective controlled study , 2006 .
[35] P. Giral,et al. 738 A one year randomized, placebo-controlled, double-blind trial of rosiglitazone in non-alcoholic steatohepatitis: Results of the flirt pilot trial , 2006 .
[36] A. Andriulli,et al. 506 Pegylated interferon alpha-2b monotherapy and in combination with ribavirin in chronic hepatitis delta , 2006 .
[37] P. Roderick,et al. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. , 2006, Journal of hepatology.
[38] N. Afdhal,et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. , 2006, Gastroenterology.
[39] G. D'offizi,et al. Liver enzyme elevation in hepatitis C virus (HCV)-HIV-coinfected patients prior to and after initiating HAART: role of HCV genotypes. , 2006, AIDS research and human retroviruses.
[40] M. Pinzani,et al. Non-invasive evaluation of hepatic fibrosis: don’t count your chickens before they’re hatched , 2006, Gut.
[41] G. Sotgiu,et al. Influence of Genotype 3 Hepatitis C Coinfection on Liver Enzyme Elevation in HIV-1-Positive Patients After Commencement of a New Highly Active Antiretroviral Regimen: Results From the EPOKA-MASTER Cohort , 2006, Journal of acquired immune deficiency syndromes.
[42] M. Ziol,et al. Diagnosis of Hepatic Fibrosis and Cirrhosis by Transient Elastography in HIV/Hepatitis C Virus-Coinfected Patients , 2006, Journal of acquired immune deficiency syndromes.
[43] C. Datz,et al. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection. , 2006, Journal of hepatology.
[44] J. Torre-Cisneros,et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease , 2006, AIDS.
[45] A. Lazzarin,et al. Liver Fibrosis in HIV-Positive Patients With Hepatitis C Virus: Role of Persistently Normal Alanine Aminotransferase Levels , 2006, Journal of acquired immune deficiency syndromes.
[46] P. Pontisso,et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus–coinfected patients , 2006, Hepatology.
[47] J. Kaldor,et al. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies , 2006, Journal of viral hepatitis.
[48] T. Heeren,et al. HIV Infection Does Not Affect the Performance of Noninvasive Markers of Fibrosis for the Diagnosis of Hepatitis C Virus-Related Liver Disease , 2005, Journal of acquired immune deficiency syndromes.
[49] M. Bajaj,et al. Disseminated cysticercosis involving orbit, brain and subcutaneous tissue. , 2005, The Journal of infection.
[50] M. Vogel,et al. Orthotopic liver transplantation in human immunodeficiency virus (HIV)‐positive patients: Outcome of 7 patients from the Bonn cohort , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[51] M. Pirisi,et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases , 2005, Hepatology.
[52] A. Perelson,et al. Mutagenic effects of ribavirin in vivo. , 2005, Journal of hepatology.
[53] L. Piroth. Liver steatosis in HIV-infected patients. , 2005, AIDS reviews.
[54] T. Nakajima,et al. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. , 2005, Journal of hepatology.
[55] P. Tien. Management and Treatment of Hepatitis C Virus Infection in HIV-Infected Adults: Recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office1 , 2005, The American Journal of Gastroenterology.
[56] V. Soriano,et al. Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Results of a Randomized Clinical Study , 2005, Antimicrobial Agents and Chemotherapy.
[57] A. Mocroft,et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. , 2005, The Journal of infectious diseases.
[58] S. Hernandez,et al. Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain , 2005, AIDS.
[59] V. Soriano,et al. Hepatic and Renal Safety Profile of Tenofovir in HIV-Infected Patients with Hepatitis C, Including Patients on Interferon Plus Ribavirin , 2005, HIV clinical trials.
[60] F. Carrat,et al. Risk Factors for Symptomatic Mitochondrial Toxicity in HIV/Hepatitis C Virus-Coinfected Patients During Interferon Plus Ribavirin-Based Therapy , 2005, Journal of acquired immune deficiency syndromes.
[61] B. Gazzard,et al. Transmission of Hepatitis C Virus Among HIV-Positive Homosexual Men and Response to a 24-Week Course of Pegylated Interferon and Ribavirin , 2005, Journal of acquired immune deficiency syndromes.
[62] J. Macías,et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes , 2005, Gut.
[63] E. Bini,et al. Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial. , 2005, Journal of acquired immune deficiency syndromes.
[64] V. Soriano,et al. Early Monitoring of Ribavirin Plasma Concentrations May Predict Anemia and Early Virologic Response in HIV/Hepatitis C Virus-Coinfected Patients , 2005, Journal of acquired immune deficiency syndromes.
[65] V. de Lédinghen,et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study , 2005, Gut.
[66] N. Afdhal,et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. , 2005, Journal of hepatology.
[67] V. Soriano,et al. Impact of Ribavirin Exposure on Early Virological Response to Hepatitis C Therapy in HIV-Infected Patients with Chronic Hepatitis C , 2005, Antiviral therapy.
[68] N. Shire,et al. Outcomes among patients with end-stage liver disease who are coinfected with HIV and hepatitis C virus. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[69] E. Wilkins,et al. BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis B virus infection (2005) , 2005, HIV medicine.
[70] V. Soriano,et al. Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations. , 2005, AIDS research and human retroviruses.
[71] A. Andriulli,et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. , 2005, The New England journal of medicine.
[72] B. Clotet,et al. Results of a Study of Prolonging Treatment with Pegylated Interferon-α2A plus Ribavirin in HIV/HCV-Coinfected Patients with No Early Virological Response , 2005, Antiviral therapy.
[73] Giorgio Palù,et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. , 2005, Journal of hepatology.
[74] E. Timmermans,et al. Mitochondrial Dna Depletion in HIV-Infected Patients is More Pronounced with Chronic Hepatitis C and Enhanced following Treatment with Pegylated Interferon plus Ribavirin , 2005, Antiviral therapy.
[75] Sheng-Nan Lu,et al. Combination therapy with interferon‐α and ribavirin in patients with dual hepatitis B and hepatitis C virus infection , 2005, Journal of gastroenterology and hepatology.
[76] M. Lederman,et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. , 2005, The Journal of infectious diseases.
[77] V. Soriano,et al. Hepatitis C Viremia in HIV/HCV-Coinfected Patients: Lower Levels in Presence of Chronic Hepatitis B , 2005, HIV clinical trials.
[78] R. Andrade,et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. , 2005, Gastroenterology.
[79] H. Jessen,et al. Treatment of acute hepatitis C infection in HIV‐infected patients: a retrospective analysis of eleven cases , 2005, Journal of viral hepatitis.
[80] C. Quereda,et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[81] A. Alberti. Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. , 2005, Journal of hepatology.
[82] N. Margot,et al. In Vitro Combination Studies of Tenofovir and Other Nucleoside Analogues with Ribavirin against HIV-1 , 2005, Antiviral therapy.
[83] P. Duca,et al. Open, Randomized, Multicentre Italian Trial on Peg-Ifn plus Ribavirin versus Peg-Ifn Monotherapy for Chronic Hepatitis C in HIV-Coinfected Patients on Haart , 2005, Antiviral therapy.
[84] V. de Lédinghen,et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. , 2005, Gastroenterology.
[85] A. Bruchfeld,et al. High‐dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C , 2005, Hepatology.
[86] Raymond T Chung,et al. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. , 2005, Gastroenterology.
[87] Ming‐Lung Yu,et al. Viral Interaction and Responses in Chronic Hepatitis C and B Coinfected Patients with Interferon-Alpha plus Ribavirin Combination Therapy , 2005, Antiviral therapy.
[88] Christos Christidis,et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C , 2005, Hepatology.
[89] A. Perelson,et al. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection , 2004, Nature.
[90] F. Carrat,et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. , 2004, JAMA.
[91] K. Reddy,et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. , 2004, Gastroenterology.
[92] J. Pawlotsky,et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. , 2004, Journal of hepatology.
[93] R. Bruno,et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome , 2004, AIDS.
[94] Richard D Moore,et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir , 2004, AIDS.
[95] J. Guest,et al. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[96] A. Andriulli,et al. Treatment of patients with HCV infection with or without liver biopsy , 2004, Journal of viral hepatitis.
[97] B. McGovern. Hepatic safety and HAART. , 2004, Journal of the International Association of Physicians in AIDS Care.
[98] A. Wohl,et al. Survival in patients with HIV infection and viral hepatitis B or C: a cohort study , 2004, AIDS.
[99] D. Dieterich,et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy , 2004, AIDS.
[100] A. León,et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients , 2004, AIDS.
[101] D. Wendum,et al. Significance of hepatitis C virus coinfection with persistently normal alanine aminotransferase levels in HIV‐1‐infected patients , 2004, HIV medicine.
[102] V. Soriano,et al. Long-Term Follow-Up of HIV-Infected Patients with Chronic Hepatitis C Virus Infection Treated with Interferon-Based Therapies , 2004, Antiviral therapy.
[103] Felipe García,et al. Depressive Symptoms after Initiation of Interferon Therapy in Human Immunodeficiency Virus-Infected Patients with Chronic Hepatitis C , 2004, Antiviral therapy.
[104] P. Volberding,et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. , 2004, The New England journal of medicine.
[105] J. Montaner,et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. , 2004, The New England journal of medicine.
[106] V. Soriano,et al. Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients. , 2004, AIDS research and human retroviruses.
[107] R. Tubiana,et al. Acute hepatitis C in HIV‐infected men who have sex with men , 2004, HIV medicine.
[108] E. Sagnelli,et al. Influence of Chronic Coinfection with Hepatitis B and C Virus on Liver Histology , 2004, Infection.
[109] H. Saito,et al. Efficacy of non-invasive elastometry on staging of hepatic fibrosis. , 2004, Hepatology research : the official journal of the Japan Society of Hepatology.
[110] E. Schiff,et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. , 2004, Gastroenterology.
[111] B. Gazzard,et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study , 2004, The Lancet.
[112] William M. Lee,et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. , 2004, Gastroenterology.
[113] C. Giffen,et al. Treatment of chronic hepatitis C in HIV/HCV‐coinfection with interferon α‐2b+ full‐course vs. 16‐week delayed ribavirin , 2004, Hepatology.
[114] I. Suh,et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study , 2004, BMJ : British Medical Journal.
[115] P. Marcellin,et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.
[116] P. Marcellin,et al. Effect of peginterferon alfa‐2a on liver histology in chronic hepatitis C: A meta‐analysis of individual patient data , 2004, Hepatology.
[117] V. Soriano,et al. Care of patients with hepatitis C and HIV co-infection. , 2004, AIDS.
[118] A. Muriel,et al. High Rate of Didanosine-Related Mitochondrial Toxicity in HIV/HCV-Coinfected Patients Receiving Ribavirin , 2004, Antiviral therapy.
[119] V. Paradis,et al. Sampling variability of liver fibrosis in chronic hepatitis C , 2003, Hepatology.
[120] G. Lüchters,et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection , 2003, The Lancet.
[121] A. Perelson,et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. , 2003, The Journal of infectious diseases.
[122] N. Heaton,et al. Survival of human immunodeficiency virus-infected liver transplant recipients. , 2003, The Journal of infectious diseases.
[123] Richard D Moore,et al. Hospitalization Rates Differ by Hepatitis C Status in an Urban HIV Cohort , 2003, Journal of acquired immune deficiency syndromes.
[124] P. Morlat,et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study) , 2003, AIDS.
[125] N. Gruener,et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. , 2003, Gastroenterology.
[126] V. Soriano,et al. Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients , 2003 .
[127] V. Soriano,et al. Hepatitis C Virus-Rna Clearance in HIV-Coinfected Patients with Chronic Hepatitis C Treated with Pegylated Interferon plus Ribavirin , 2003, Antiviral therapy.
[128] M. Buti,et al. Extending combination therapy with peginterferon alfa‐2b plus ribavirin for genotype 1 chronic hepatitis C late responders: A report of 9 cases , 2003, Hepatology.
[129] C. Puoti. HCV carriers with persistently normal aminotransferase levels: normal does not always mean healthy. , 2003, Journal of hepatology.
[130] C. Katlama,et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients , 2003, AIDS.
[131] V. Soriano,et al. Treatment of chronic hepatitis C virus infection: we must target the virus or liver fibrosis? , 2003, AIDS.
[132] Y. Jeng,et al. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients , 2003, Hepatology.
[133] G. Sirera,et al. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co‐infected patients , 2003, Journal of viral hepatitis.
[134] V. Soriano,et al. Incidence of Liver Injury After Beginning Antiretroviral Therapy with Efavirenz or Nevirapine , 2003, HIV clinical trials.
[135] R. Roldán,et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[136] T. Poynard,et al. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy , 2003, AIDS.
[137] B. Clotet,et al. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches , 2003, AIDS.
[138] C. Quereda,et al. Pegylated interferon α2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients , 2003, AIDS.
[139] M. S. Wilson,et al. The Clinical Spectrum of Hepatitis C Virus in HIV Coinfection , 2003, Journal of acquired immune deficiency syndromes.
[140] M. Kazatchkine,et al. Severe liver mitochondriopathy with normal liver histology and normal lactate levels in patients receiving nucleoside analogues. , 2002, AIDS.
[141] V. Soriano,et al. Weight loss in HIV-infected patients. , 2002, The New England journal of medicine.
[142] William M. Lee,et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. , 2002, Gastroenterology.
[143] Llorenç Quintó,et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model , 2002, Hepatology.
[144] E. Schiff,et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection , 2002, American Journal of Gastroenterology.
[145] Dieter Häussinger,et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.
[146] A. Alberti,et al. Prevalence of Liver Disease in a Population of Asymptomatic Persons with Hepatitis C Virus Infection , 2002, Annals of Internal Medicine.
[147] Richard D Moore,et al. Hepatitis C and progression of HIV disease. , 2002, JAMA.
[148] A. Zanella,et al. Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels , 2002, Annals of Internal Medicine.
[149] M. Puoti,et al. Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). , 2002, Journal of hepatology.
[150] V. Soriano,et al. Role of Hepatitis C Virus Genotype in the Development of Severe Transaminase Elevation After the Introduction of Antiretroviral Therapy , 2002, Journal of acquired immune deficiency syndromes.
[151] V. Soriano,et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. , 2002, AIDS.
[152] V. Soriano,et al. Liver toxicity caused by nevirapine. , 2002, AIDS.
[153] R. Chaisson,et al. Hepatotoxicity associated with nevirapine or efavirenz‐containing antiretroviral therapy: Role of hepatitis C and B infections , 2002, Hepatology.
[154] A. Aceti,et al. Hepatotoxicity Development During Antiretroviral Therapy Containing Protease Inhibitors in Patients With HIV: The Role of Hepatitis B and C Virus Infection , 2002, Journal of acquired immune deficiency syndromes.
[155] C. Trautwein,et al. Treatment of acute hepatitis C with interferon alfa-2b. , 2001, The New England journal of medicine.
[156] J. González-lahoz,et al. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. , 2001, AIDS research and human retroviruses.
[157] P. Marcellin,et al. Prospective study on anti‐hepatitis C virus–positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA , 2001, Hepatology.
[158] M. Buti,et al. Role of hepatitis B, C, and D viruses in dual and triple infection: Influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference , 2001, Hepatology.
[159] Andrew Phillips,et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy , 2001, AIDS.
[160] D. Snydman,et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[161] A. Lafeuillade,et al. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection , 2001, The Lancet.
[162] P. Reiss,et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection , 2000, AIDS.
[163] M. Dubé. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[164] J. Wong,et al. Watchful Waiting with Periodic Liver Biopsy versus Immediate Empirical Therapy for Histologically Mild Chronic Hepatitis C: A Cost-Effectiveness Analysis , 2000, Annals of Internal Medicine.
[165] G. Hajian,et al. Population Pharmacokinetic and Pharmacodynamic Analysis of Ribavirin in Patients With Chronic Hepatitis C , 2000, Therapeutic drug monitoring.
[166] F. Montagnese,et al. Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients? , 2000, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[167] F. Degos,et al. Practices of Liver Biopsy in France: Results of a Prospective Nationwide Survey , 2000, Hepatology.
[168] M. Kazatchkine,et al. Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy. , 2000, AIDS.
[169] D. Vlahov,et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. , 2000, JAMA.
[170] R. Torella,et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. , 2000, Gastroenterology.
[171] R. Chaisson,et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. , 2000, JAMA.
[172] C. Garret,et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. , 1999, Gastroenterology.
[173] C. Katlama,et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients , 1999, Hepatology.
[174] M. Velasco,et al. Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient. , 1999, The New England journal of medicine.
[175] C. Hart,et al. Effect of ribavirin on zidovudine efficacy and toxicity in vitro: a concentration-dependent interaction. , 1998, AIDS research and human retroviruses.
[176] V. Soriano,et al. Hepatotoxicity after introduction of highly active antiretroviral therapy. , 1998, AIDS.
[177] S. Rossi,et al. Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection. , 1998, Journal of hepatology.
[178] M. Vidaud,et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity , 1998, Hepatology.
[179] Lenzo Np,et al. Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report. , 1997 .
[180] J. Ludwig,et al. The long‐term pathological evolution of chronic hepatitis C , 1996, Hepatology.
[181] H. Conjeevaram,et al. Volunteer Blood Donors with Antibody to Hepatitis C Virus: Clinical, Biochemical, Virologic, and Histologic Features , 1995, Annals of Internal Medicine.
[182] M. Shindo,et al. The virological and histological states of anti‐hepatitis C virus–positive subjects with normal liver biochemical values , 1995, Hepatology.
[183] J. González-lahoz,et al. More severe course of delta hepatitis in HIV-infected patients [L] , 1995, Genitourinary medicine.
[184] M. Mondelli,et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities , 1995, Hepatology.
[185] R. Robinson. Economic Evaluation and Health Care Cost-effectiveness analysis , 2006 .
[186] J. Rodríguez-Orengo,et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. , 2006, Journal of hepatology.
[187] C. B. Hare,et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. , 2006, Journal of acquired immune deficiency syndromes.
[188] Marina Núñez,et al. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. , 2006, Journal of hepatology.
[189] V. Soriano. Treatment of chronic hepatitis C in HIV-positive individuals: selection of candidates. , 2006, Journal of hepatology.
[190] M. Buti,et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. , 2006, Journal of hepatology.
[191] A. Andriulli,et al. P.324 Pegylated interferon alpha-2b monotherapy and in combination with ribavirin in chronic hepatitis delta , 2006 .
[192] M. Alter,et al. Epidemiology of viral hepatitis and HIV co-infection. , 2006, Journal of hepatology.
[193] J. Miro,et al. Management of end stage liver disease (ESLD): what is the current role of orthotopic liver transplantation (OLT)? , 2006, Journal of hepatology.
[194] J. Gerber,et al. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[195] J. J. de la Cruz,et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. , 2004, Clinical Infectious Diseases.
[196] C. Katlama,et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. , 2002, AIDS.
[197] F. Callea,et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. , 2001, The Journal of infectious diseases.
[198] E. Zafrani,et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. , 1999, Journal of hepatology.
[199] N. Lenzo,et al. Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report. , 1997, AIDS.
[200] M. Colombo,et al. Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection. , 1996, Gastroenterology.